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ABSTRACT 
The success of Onpattro™ (patisiran) clearly demonstrates the utility of lipid nanoparticle (LNP) 
systems for enabling gene therapies. These systems are composed of ionizable cationic lipids, 
phospholipid, cholesterol, and polyethylene glycol (PEG)-lipids, and are produced through rapid-
mixing of an ethanolic-lipid solution with an acidic aqueous solution followed by dialysis into 
neutralizing buffer. A detailed understanding of the mechanism of LNP formation is crucial to 
improving LNP design. Here we use cryogenic transmission electron microscopy and fluorescence 
techniques to further demonstrate that LNP are formed through the fusion of precursor, pH-
sensitive liposomes into large electron-dense core structures as the pH is neutralized. Next, we 
show that the fusion process is limited by the accumulation of PEG-lipid on the emerging particle. 
Finally, we show that the fusion-dependent mechanism of formation also applies to LNP 
containing macromolecular payloads including mRNA, DNA vectors, and gold nanoparticles. 
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Onpattro™ (patisiran) is the first RNA interference therapeutic approved by the FDA and 
EMA.1, 2 The technology enabling the delivery of therapeutic short interfering RNA (siRNA) is 
based on lipid nanoparticles (LNP). These systems are composed of ionizable cationic lipids (e.g. 
2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (KC2)3 or heptatriaconta-6,9,28,31-
tetraen-19-yl-4-(dimethylamino)butanoate (MC3)4), phospholipid, cholesterol and polyethylene 
glycol-lipid.5, 6 LNP are generated through rapid-mixing techniques7 where an ethanolic lipid 
solution is diluted into an acidic aqueous phase containing the anionic macromolecules. We have 
previously shown that LNP prepared in this way display high entrapment efficiencies (> 85%) for 
anionic macromolecules such as siRNA8 and plasmid DNA (pDNA)9, 10, or colloidal gold 
nanoparticles (GNP).10  
LNP-siRNA systems display an electron-dense core as observed by cryogenic transmission 
electron microscopy (cryo-TEM).11, 12 It was originally suggested that this electron-dense core 
reflects inverted micellar structures generated by the association of ionizable cationic lipid with 
the anionic payload.12 These hydrophobic structures were hypothesized to aggregate and then 
become coated with a monolayer of polar lipids such as PEG-lipids as these lipids reach their 
solubility limits in the ethanol/water mixture. This hypothesis implied that the final LNP structure 
is established during (and as a result of) the rapid-mixing process.5, 6, 8, 12, 13 Recently, we re-
examined the LNP-siRNA structure, demonstrating that the LNP electron-dense core morphology 
does not consist of inverted micelles but reflects an oil core consisting primarily of neutral 
ionizable lipid,11 and suggested that LNP-siRNA formulations are generated through fusion of 
smaller particles that occurs after the rapid-mixing procedure. While much of that work was 
performed with the ionizable lipid KC2, the same structures and mechanism of formation are seen 
for LNP with the Onpattro™ composition (containing MC3; Supporting Figure S1). 
 In this work, we further elucidate the mechanism of LNP formation following the rapid-
mixing step for LNP systems using an electron microscopy- and fluorescence-based approach. We 
examine the role of PEG-lipids in limiting the fusion process and extend our investigation of LNP 
morphology to include larger payloads such as messenger RNA (mRNA), minicircle DNA 
(mcDNA), pDNA, or GNP. Results obtained support the proposal that LNP formation occurs 
through a pH-dependent fusion process that occurs subsequent to the rapid mixing event, and that 
the formation of LNP with large payloads builds on formation of LNP formed at pH 4 that contain 
mRNA, mcDNA or pDNA. 
 
  
MATERIALS AND METHODS 
Materials 
The lipids 1,2-distearoyl-sn-glycero-3-phosphorylcholine (DSPC) and 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt) (PEG-DSPE) 
were purchased from Avanti Polar Lipids (Alabaster, AL). The ionizable amino-lipid 2,2-
dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (KC2) was synthesized by Biofine 
International (Vancouver, BC). Cholesterol was purchased from Sigma-Aldrich (St. Louis, MO). 
Heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (MC3)4 and (R)-2,3-
bis(tetradecyloxy)propyl-1-(methoxy polyethylene glycol 2000) carbamate (PEG-DMG)14 were 
synthesized as previously described. Lipophilic indocarbocyanine dyes 3,3'-
dioctadecyloxacarbocyanine perchlorate (DiO) and 1,1'-dioctadecyl-3,3,3',3'-
tetramethylindocarbocyanine perchlorate (DiI) were purchased from ThermoFisher Scientific 
(Waltham, MA). TEM grids and gold nanoparticles were purchased from Ted Pella, Inc. (Redding, 
CA). mRNA encoding firefly luciferase was purchased from TriLink Biotechnologies (San Diego, 
CA). pDNA encoding TdTomato15 was purchased from Addgene (Cambridge, MA) and prepared 
using a Qiagen Endotoxin-free Giga prep kit (Hilden, Germany). Minicircle DNA (mcDNA) was 
generated by transforming the mcDNA producer plasmids into E. coli ZYCY10P3S2T and 
purification of resulting mcDNA vectors using the Qiagen Endotoxin-free plasmid purification kit 
as previously described.16 siRNA against firefly luciferase17 was purchased from IDT (Coralville, 
IA). 
 
Preparation of empty LNP 
LNP were prepared as previously described.9, 11 Briefly, lipid components (KC2, Chol, DSPC, and 
PEG-lipid) at appropriate ratios were dissolved in ethanol to a concentration of 10-15 mM total 
lipid. For fluorescence resonance energy transfer (FRET) experiments: non-exchangeable donor 
or acceptor lipid tracers (DiO or DiI, respectively) were added to lipid mixtures at a concentration 
of 0.2 mol%.  
The aqueous phase consisted of 25 mM sodium acetate pH 4 buffer. The two solutions were mixed 
through a T-junction mixer 18, 19 at a total flow rate of 20 mL/min, and a flow rate ratio of 3:1 v/v 
(corresponding to 15:5 mL/min aqueous:organic phase). Unless otherwise specified, the resulting 
suspension was subsequently dialysed against 1000-fold volume of the same sodium acetate pH 4 
buffer or against phosphate buffered saline (PBS pH 7.4). 
For post-formation PEG-insertion studies: LNPs were prepared with KC2, DSPC and Chol (no 
PEG-lipid) using the rapid-mixing technique described above, where the ethanolic lipid phase was 
combined with a 25mM sodium acetate pH 4 buffer. Following dialysis into the same pH 4 buffer 
to remove ethanol the resulting LNPs were concentrated to achieve a final concentration of 2.5 mM 
total lipid. PEG-lipid dissolved in ethanol was added to appropriate amounts to achieve 
0.5-2.5 mol% PEG-lipid. At all molar fractions of PEG, the total amount of ethanol in the mixture 
was 1% v/v. The solutions were pipette-mixed and the resulting mixture was dialysed against 
1000-fold volume of PBS overnight. 
 
FRET-based fusion assay 
LNP-DiO, LNP-DiI or LNP-DiO/LNP-DiI mixtures (equimolar concentrations) at pH 4 or pH 7.4 
were diluted using sodium acetate pH 4 buffer or PBS pH 7.4. Samples were excited at 470 nm 
and the emission was collected between 505 - 650 nm. FRET data from each set of experiment 
were normalized to emission of donor probe (LNP-DiO) under identical conditions. Spectroscopic 
evidence for FRET could be observed by decrease of fluorescence at 505 nm and increase at 
570 nm.  
 
Preparation of LNP containing nucleic acid 
LNP-nucleic acid were prepared as previously described.9, 11 Briefly, lipid components (KC2, 
Chol, DSPC, and PEG-lipid) at appropriate ratios were dissolved in ethanol to a concentration of 
10-15 mM total lipid. Purified nucleic acid polymers were dissolved in 25 mM sodium acetate 
pH 4 buffer to achieve a ratio of 0.029 mg nucleic acid per µmol lipid (corresponding to amine-
to-phosphate (N/P) ratio of 6) unless otherwise specified. The two solutions were mixed through 
a T-junction mixer 18, 19 at a total flow rate of 20 mL/min, and a flow rate ratio of 3:1 v/v 
(corresponding to 15:5 mL/min aqueous:organic phase). The resulting suspension was 
subsequently dialysed against the same sodium acetate pH 4 buffer or directly against PBS pH 7.4. 
 
Preparation of LNP containing gold nanoparticles (GNP) 
LNP-GNP were prepared using a modified process from that described elsewhere.10 Briefly, lipid 
components (KC2, Chol, DSPC, and PEG-lipid) at appropriate ratios were dissolved in ethanol to 
a concentration of 10-15 mM total lipid. 5 nm GNP with a tannic-acid surface modification (Ted 
Pella, Redding, CA) were suspended in 25 mM sodium acetate pH 4 to a concentration of 
2.2 x 1013 GNP/µmol lipid. In order to maintain the same charge ratio (negative charges of the 
GNP to positively charged lipid), 12 nm GNP were formulated at 3.82 x 1012 GNP/µmol lipid. 
This number was generated based on maintaining a constant ratio of surface area of GNP to amount 
of lipid (1.73 x 1015 nm2/µmol lipid). The two solutions were mixed through a T-junction mixer 
18, 19 at a total flow rate of 20 mL/min, and a flow rate ratio of 3:1 v/v (corresponding to 15:5 
mL/min aqueous:organic phase). The resulting suspension was subsequently dialysed against the 
same sodium acetate pH 4 buffer or directly against PBS pH 7.4. For studies including a mixture 
of 5 and 12 nm GNP, the LNP systems were always mixed after the rapid-mixing process.  
 
Cryogenic transmission electron microscopy (cryo-TEM) 
Cryo-TEM was performed as previously described.11 LNP suspensions were concentrated to a 
final concentration of 20-25 mg/mL of total lipid and added to glow-discharged copper grids (3-5 
µL), and plunge-frozen using a FEI Mark IV Vitrobot (FEI, Hillsboro, OR) to generate vitreous 
ice. Grids were stored in liquid nitrogen until imaged. Grids were moved into a Gatan 70° cryo-
tilt transfer system pre-equilibrated to at least -180°C prior to insertion into the microscope. An 
FEI LaB6 G2 TEM (FEI, Hillsboro, OR) operating at 200 kV under low-dose conditions was used 
to image all samples. A bottom-mount FEI Eagle 4K CCD camera was used to capture all images. 
All samples (unless otherwise stated) were imaged at a 55,000x magnification with a nominal 
under-focus of 1-2 µm to enhance contrast. Sample preparation and imaging was performed at the 
UBC Bioimaging Facility (Vancouver, BC). 
 
Analysis of LNPs 
Cryo-TEM micrographs obtained for each sample were characterized for particle size (as 
compared by length to the scale bar), performed by manual counting of at least 150 LNPs to 
account for scattering interference from different morphology. Such an approach has been shown 
to closely correlate with the number-weighted average produced by dynamic light scattering.20 
Similarly, the fraction of loaded LNPs was performed manually. Lipid concentrations were 
measured using the Cholesterol E Total-Cholesterol assay (Wako Diagnostics, Richmond, VA). 




Statistical analyses were performed for all quantitative data using GraphPad. Where applicable, 
two-way ANOVAs were performed using the Tukey multiple comparison test and confidence level 
of 0.001. Similarly, where applicable an unpaired t-test was performed. All significance values are 
provided in the figure legends or in the Supporting Information. 
  
RESULTS and DISCUSSION 
FRET and Cryo-TEM studies demonstrate fusion of precursor liposomes 
Initial studies were focused on characterizing the fusion events following the rapid mixing 
of KC2/DSPC/Chol/PEG-lipid (50/10/39/1 mol%) in ethanol with an aqueous stream of 
25 mM acetate buffer pH 4 buffer to form “empty” LNP systems. The resulting mixture was then 
dialyzed against the acetate buffer to remove ethanol, or against phosphate buffered saline (PBS) 
pH 7.4 to remove solvent and neutralize the pH. In agreement with previous studies,11 the empty 
LNP display small bilayer structures at pH 4 where KC2 (pKa ∼ 6.7) is protonated but form larger 
electron-dense structures at pH 7.4 (Figure 1A/B). In order to directly demonstrate that the larger 
structures result from fusion of structures formed at pH 4, LNP were formulated with non-
exchangeable fluorescence resonance energy transfer (FRET) lipid tracers; either a donor probe 
(DiO; green; Ex 484 nm, Em 501 nm) or an acceptor probe (DiI; red; Ex 549 nm, Em 565 nm), 
which are able to act as a FRET pair when in close proximity,22 i.e. present in the same LNP. If 
the particles fuse, a FRET signal would be expected as emission at 565 nm, when excited at 470 
nm. As shown in Figure 1C (top left), when the two formulations are combined at pH 4, the 
emission profile was an additive effect of two separate LNP formulations (no FRET). However, 
when LNP-DiO and LNP-DiI were combined at pH 4 and neutralized with addition of PBS, a clear 
FRET signal was observed (Figure 1C, top right). In order to determine if lipid mixing occurred 
after the pH was raised to 7.4, LNP-DiO and LNP-DiI at pH 7.4 were combined and then the pH 
was lowered to 4 (Figure 1C, bottom left) - no FRET signal was observed. Similarly, LNP 
combined at pH 7.4 and diluted with the same buffer did not display a FRET signal (Figure 1C, 
bottom right). These data provide clear evidence that raising the pH from 4 to 7.4 promotes fusion 
of particles and that no lipid exchange occurs following this fusion process.  
 
 
Figure 1. Empty LNP observed as electron-dense structures are generated through fusion of 
smaller vesicular structures. (A) Empty LNP composed of KC2/Chol/DSPC/PEG-lipid 
(50/10/39/1 mol%) were generated at pH 4 and dialyzed into pH 4 buffer to remove solvent, or 
dialysed into PBS pH 7.4 to remove solvent and neutralize the pH. Scale bar = 100 nm. (B) Particle 
sizes of LNP at pH 4 and pH 7.4 as determined by manual measurement of 200 particles. Unpaired 
t-test, p < 0.0001. (C) LNP-DiO (donor) and LNP-DiI (acceptor) systems were combined under 
different conditions to determine if particle fusion generated a FRET signal. Top left: Formulations 
prepared in pH 4 were combined in pH 4 buffer. Top right: Formulations prepared in pH 4 buffer 
were combined and the pH was neutralized (pH 7.4). Note this is the only condition which resulted 
in FRET. Bottom left: Formulations prepared in PBS were combined in pH 4 buffer. Bottom right: 
Formulations prepared in PBS were combined and diluted in PBS. Each panel has an inset 
describing the experiment. 
 
 
PEG-lipids limit fusion and dictate particle size 
We next examined the role of PEG-lipids in determining the equilibrium size of these LNP. 
Previous work has shown that PEG-lipids reside primarily on the LNP surface where they exhibit 
a large area per molecule at the polar-non-polar interface of approximately 26 nm2 (for PEG2000)8. 
As a result, the proportion of PEG-lipid dictates the size of the LNP as the concentration of PEG-
lipid on the surface approaches a critical level that inhibits further fusion.8, 12, 21 Here, we show 
that empty LNP composed of KC2/DSPC/Chol/PEG-lipid (50/10/37.5-39.5/0.5-2.5 mol%) form 
bilayer structures at pH 4 (Figure 2A). Regardless of PEG-lipid content, the particle size at pH 4 
is ~ 17 nm (Figure 2B), but ranges from 31.9 nm (2.5 mol%) to 58.1 nm (0.5 mol%) at pH 7.4 
(Figure 2C), indicating that the PEG-lipid exerts its size-limiting role during neutralization of the 
pH. In order to demonstrate this more directly, LNPs composed of only KC2, DSPC and 
cholesterol (without PEG) were formulated by ethanol dilution/rapid mixing at pH 4 and dialyzed 
into the pH 4 buffer to remove solvent. PEG-lipid was then added into the LNP suspension from 
ethanol stocks, briefly mixed and the pH raised to pH 7.4 through dialysis. The resulting particle 





Figure 2. PEG-lipid limits the number of particles that fuse to form the final LNP suspension 
at pH 7.4. (A) LNP composed of KC2/DSPC/Chol/PEG-lipid at molar ratios of 50/10/37.5-
39.5/0.5-2.5 (respectively) were prepared in pH 4 buffer through rapid-mixing, and dialyzed into 
pH 4 buffer to remove solvent. Scale bar = 100 nm. (B) Particle sizes of LNP at pH 4 as determined 
by manual measurement of 200 particles. (C) Particle size of LNP prepared at pH 7.4 by addition 
of PEG-lipid at various stages of LNP formation. Formulations composed of KC2, DSPC, and 
Chol (with or without PEG-lipid) were generated using the rapid-mixing method. The pre-formed 
LNP mixture contained the appropriate amount of PEG-lipid in the ethanolic phase during rapid-
mixing (black bars). For another set of formulations (termed post-inserted), particles were 
prepared without PEG-lipid and dialysed into pH 4 buffer to remove solvent. PEG-lipid was then 
added into the LNP suspension from ethanol stocks (total ethanol content was 1% v/v) and dialysed 
against PBS overnight (grey bars). The resulting particles were analysed by DLS. Results indicate 
number mean ± standard deviation.  
 
  
Since the area per membrane lipid at the membrane-water interface is dependent on the 
size of the headgroup,23 it would be expected that the area per molecule of the PEG-lipids will 
depend on the size of the PEG-moiety. LNPs were formulated with PEG-lipid covering the PEG 
molecular weight range of 350 – 3000 g/mol (at molar fractions of 0.25 – 5 mol%). As shown in 
Supporting Figure 2, decreasing the size of the PEG-chain results in significantly larger particles, 
and increasing the molar fraction of PEG-lipid results in smaller particles. Using the mathematical 
model described previously,8 the corresponding area per PEG-lipid was determined to be 
1.3-2 nm2 for PEG350 (large size distributions), 6.5 nm2 for PEG750, 26 nm2 for PEG2000 (as 
previously observed)8, and 45 nm2 for PEG3000.  
 
LNP formulations of mRNA, mcDNA and pDNA are formed through fusion 
It has been demonstrated previously that the ethanol-dilution rapid-mixing formulation 
process can also be applied to efficiently encapsulate large RNA and DNA payloads such as 
mRNA10, 24 and plasmid DNA.9, 10 It may be expected that the large size of these molecules will 
influence the size of the LNP formed at pH 4 that contain nucleic acid. LNP were formulated with 
mRNA (1.9 kb), mcDNA (1.4 and 3.4 kb-pairs) and plasmid DNA (5.6 kb-pairs) and characterized 
by cryo-TEM. It was found that LNP at pH 4 displayed two distinct populations: small liposomal 
structures and larger electron-dense particles (Figure 3A). The electron-dense particles at pH 4 
were marginally smaller than the electron-dense particles observed at pH 7.4 (Figure 3B). The 
obvious difference between siRNA and pDNA is the size of the 21 bp duplex (42 negative charges) 
as compared to 5.6 kbp (11,200 negative charges). At an amine-to-phosphate (N/P) ratio of 1.5 
(shown to be necessary to fully condense pDNA25), this corresponds to 1.68 x 104 ionizable 
cationic lipids per pDNA. Assuming a lipid density of 0.9 g/mL, this corresponds to a lipid volume 
of 3.66 x 104 nm3 and a plasmid volume of 4.36 x 103 nm3/plasmid. The resultant LNP would be 
42.8 nm in diameter if it contained one plasmid, and 52.7 nm if it contained two plasmids. The 
large electron-dense core structures (at pH 4) are 47.3 nm in diameter and likely contain one or 
two plasmids per particle. At pH 7.4, the average particle size increased to 59.4 nm. It is probable 
that the formulation is composed of a mixture of empty and pDNA-loaded LNP, however the cryo-
TEM approach is unable to distinguish between these particles. It should be noted that for mRNA 
and mcDNA, the electron-dense structures (at pH 4) are larger than expected (calculated diameters 
for mRNA: 26.6 nm, mcDNA: 29.0 nm for 1.9 kbp and 36.7 nm for 3.4 kbp), this can be attributed 
to the presence of particles containing multiple mRNAs26 or more than one mcDNA vector (i.e. 
multiple monomers or concatemers).27  
  
 
Figure 3. LNP formations of various large nucleic acid polymers undergo fusion as the pH is 
neutralized to generate the final LNP system. (A) LNP composed of KC2/DSPC/Chol/PEG-
lipid (50/10/39/1 mol%) as described elsewhere,9, 10 were prepared with nucleic acids (mRNA, 
mcDNA (1.4 and 3.4 kbp), and pDNA (5.6 kpb)) at pH 4 and dialyzed into pH 4 buffer to remove 
ethanol, or pH 7.4 buffer to remove ethanol and neutralize the pH. The resulting suspensions were 
concentrated and analyzed by cryo-TEM. Scale bar = 100 nm. (B) Particle sizing data of LNP 
systems at pH 4 divided into two categories: liposomes and electron-dense core structures, and 
particles at pH 7.4. In all cases n = 200, except for electron-dense core structures at pH 4, n = at 
least 40. 2-way ANOVA with Tukey’s multiple comparisons correction was used to determine 




GNPs shed light on the role and location of payload in LNP formation 
The final set of studies concerned LNP systems containing GNP where the difference in 
density allows the negatively charged payload to be readily tracked using cryo-TEM. Here we first 
examined these structures at pH 4 and pH 7.4 by utilizing 5 nm GNP (Figure 4A/B, respectively) 
and 12 nm GNP (Figure 4C/D, respectively). The negative charge on GNPs results from the tannic-
acid capping agent. Assuming a constant number of particles per volume, increasing the particle 
size would result in a different positive-to-negative charge ratio. To account for this, LNP-GNP 
formulations were generated at a GNP surface area-to-lipid ratio of 1.73 x 1015 nm2/µmol lipid. 
LNP systems clearly display evidence of bilayer structures at pH 4 (Figure 4A/C), and much larger 
electron-dense particles at neutral pH (Figure 4B/D). This indicates that the particles generated at 
pH 4 fully entrap the anionic payload during formation and the payload is located in structures that 
appear as electron-dense. Electron-dense particles at pH 4 are likely those that contain large nucleic 
acids (i.e. mRNA or DNA vectors), while other particles (i.e. small unilamellar vesicles) are 
payload-free. 
It is of interest to determine whether LNP-GNP particles at pH 4 participated in the fusion 
process as the pH is raised or were “fully formed”. LNP-GNP formulations were mixed at various 
stages of particle formation and imaged by cryo-TEM. First, LNP formulations of 
KC2/DSPC/Chol/PEG-lipid (50/10/39/1 mol%) containing both 5 and 12 nm GNP at pH 4 were 
combined and imaged (Figure 4E). The resulting mixture displayed electron-dense particles 
containing either 5 or 12 nm GNPs, but no particles containing both GNP types. Next, LNP-GNP 
systems at pH 7.4 were combined (Figure 4F). This mixture displayed electron-dense LNP 
containing either 5 or 12 nm GNPs suggesting no payload exchange between fully formed LNP. 
Third, when LNP-GNP formulations containing 5 nm GNP and 12 nm GNP  were combined 
immediately after rapid-mixing at pH 4 and then dialyzed into PBS pH 7.4 to neutralize and 
remove solvent, LNP contained either 5 nm GNP, 12 nm GNP or a mixture of the two GNP sizes 
(Figure 4G) indicating that the fusion process is not affected by the presence of encapsulated GNP. 
A similar experiment was performed combining LNP-GNP systems at pH 4 in the absence of 
solvent followed by neutralization using dialysis against PBS pH 7.4 (Figure 4H). As in Figure 
4G, LNP contained either 5 nm GNP, 12 nm GNP or a mixture of both 5 and 12 nm GNPs. As 
observed for all other LNP formulations, particles at pH 4 were significantly smaller than those at 
pH 7.4 (Figure 4I). Importantly, the use of GNPs show clearly that loaded LNP formulations can 
contain empty LNP, and that the fraction of empty LNP is dictated by the size of the payload 
(Figure 4J). Thus, formulations entrapping larger nucleic acid sequences are more likely to contain 




Figure 4. LNP-GNP formulations containing either 5 or 12 nm GNP suggest particles with 
GNP at pH 4 participate in further fusion. LNP composed of KC2/DSPC/Chol/PEG-lipid 
(50/10/39/1 mol%) were prepared with 5 nm GNP (2.2 x1013 GNP/umol lipid) or 12 nm GNP (3.8 
x 1012 GNP/umol lipid) to maintain a constant GNP surface area of 1.73 x 1015 nm2/umol lipid. 
LNP-GNP5nm were imaged by Cryo-TEM at pH 4 (A), and in PBS pH 7.4 (B). LNP-GNP12nm were 
imaged by Cryo-TEM at pH 4 (C), and at pH 7.4 (D). (E) The two formulations at pH 4 were 
combined and imaged. (F) Similarly, the formulations were prepared separately at pH 7.4 and then 
combined and imaged. (G) LNP-GNP systems were combined immediately following rapid-
mixing (in the presence of 25% ethanol) and the pH raised to 7.4. (H) LNP-GNP at pH 4 were 
combined at pH 4 after dialysis to remove solvent, and the pH was neutralized. Scale bar = 100 
nm. (I) Particle sizes of LNP at pH 4 and pH 7.4 as determined by manual measurement of 200 
particles. 2-way ANOVA with Tukey’s multiple comparisons correction was used to determine 
statistical difference. LNP-GNP at pH 7.4 are the same size. For detailed comparisons see 
Supporting Information. (J) Ten fields of Cryo-TEM images were analysed to determine the 
number of particles at pH 7.4 that are associated with GNP. The total number of particles counted 




The results presented in this work show that LNP systems, regardless of payload size, form 
through fusion of smaller particles as result of the pH neutralization step rather than the rapid-
mixing step. This fusion process proceeds until the final particle accumulates sufficient PEG-lipid 
on the surface to inhibit further fusion. Thus, the LNP size is dictated by the PEG-lipid content, as 
expected larger proportions of PEG-lipids with smaller PEG moieties are required to achieve a 
given size. Finally, while the presence of payload does not affect subsequent fusion during pH 
neutralization, the size of the payload clearly influences the distribution of payload amongst the 
LNP formed. In particular, larger payloads such as mRNA, mcDNA and pDNA are more likely to 
lead to a population of loaded LNP and “empty” LNP.  
In summary, the fusion-dependent process of LNP formation leads to a more detailed 
understanding of the mechanism of formation and the structures of LNP-nucleic acid complexes 
formed. Such understanding is basic for the design of more potent LNP formulations of nucleic 
acid polymers for gene therapy applications.   
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